(more)

How standards of conduct set half a world away are shaping big companies' behavior. (more)

Microsoft's top geek and his newest tech guru explain why they love--and hate--e-mail, and how they plan to fix it. (more)

Akimbo uses broadband Internet to deliver shows to your TV that you're not likely to see anywhere else--unless, perhaps, you live in Turkey. So stay tuned. (more)

With ten shows set to air this fall, producer Jerry Bruckheimer is morphing into a TV czar. (more)

An era of corporate-crime fighting is ending. What's to keep fraudsters from striking again? Fear, and a stock market stuck in neutral. (more)

Has corporate America lost its nerve? Not when companies like GE and GM are taking huge gambles on the future. (more)

"Okay, everybody out of the canyon!" radioed Don Mackey to his beleaguered firefighters. For hours, they had been clearing a corridor on Storm King Mountain to thwart a spreading wildfire. Now that path had become the crew's only way out. Eighteen people were sprinting for their lives. Could they reach safety? A CASE STUDY IN LIFE-AND-DEATH DECISION-MAKING. (more)

Nine decision-making pitfalls--and nine simple devices to beat them. (more)

SECOND IN A SERIES OF ANNIVERSARY SPECIALS (more)

Many of these epic decisions were breathtakingly smart. Some were appallingly stupid. But all of them shaped the modern world of business. (more)

How does the most powerful U.S. small-business lobbyist prevail over the opinion polls? (more)

Most entrepreneurs want to get business, not turn it away. But sometimes a customer isn't worth keeping. (more)

Nick Calamos of the top-ranked Calamos Growth fund sees big profits to come in e-retail. (more)

Riding high in Hollywood, the comic-book company is pursuing a risky new growth plan. (more)

Why buying during a frenzy is often saner than it might appear. (more)

Seemingly in a bubble of its own, the search giant has everything going its way. (more)

At the height of the Internet bubble, these naysayers refused to believe the hype. (more)

A mega-merger that worked. R&D that's paying off. While rivals like Merck and Pfizer suffer, Novartis has confounded drugmaking odds. (more)

The inside story of how researchers at Novartis may be on the verge of something big--or may come up dry. (more)